Yardley, PA, June 28, 2022 (GLOBE NEWSWIRE) — Norstella, an organization that helps life sciences companies navigate the complexities of the drug life cycle, and Citeline (formerly Pharma Intelligence)""a leading provider of specialist intelligence, data and software for clinical trials, drug development and regulatory compliance""have announced an agreement to merge the companies.
By uniting Norstella, which is comprised of four prominent pharmaceutical solutions providers""Evaluate, MMIT, Panalgo and The Dedham Group""with Citeline, the combined company will be well positioned to help life sciences companies reach patients faster by providing clients with the intelligence and answers they need from early clinical development through to commercialization. This move reflects the shared goal of becoming an end–to–end solution provider, helping patients access life–saving therapies.
As life sciences companies drive innovation toward more specialized therapeutics across all disease areas including oncology and rare disease, and patient populations become more targeted, they need to make critical decisions about how to bring the right drugs to market, how to construct clinical trials leveraging the latest innovations in real–world data and data science""and with end points that consider future payer reimbursement decisions""and, ultimately, how to reach patients in need.
"Accelerating innovation and ensuring that every patient gets the therapy that they need is our North Star," said Norstella CEO Mike Gallup. "By bringing clinical and commercial intelligence together""along with real–world data""the combined company will be well positioned to deliver on its mission."
Together, Norstella and Citeline will play a critical role in helping pharmaceutical manufacturers plan for and overcome barriers to access, not just during clinical trials but at every stage in the drug development life cycle. Citeline's solutions, including its portfolio of clinical trial products, provide insights that improve the speed and efficiency of clinical trials and reduce risk. Now, the Citeline solutions""along with MMIT's PAR data and other complementary Norstella data assets""can be powered by Panalgo's Instant Health Data Analytics platform to provide transformative answers that will improve workflow and decision–making and, ultimately, help products get to market and to patients quicker than ever before.
"At Citeline, our mission is to accelerate the connection of treatments to patients and patients to treatments. Ultimately, this marriage of commercial and clinical capabilities will advance the mission and enable the pharmaceutical C–suite to manage portfolio strategy like never before," said Ramsey Hashem, CEO, and Jay Nadler, Executive Chair, of Citeline. "This includes deciding which drug to bring to market, what new indications to pursue for a drug and how to target patients for clinical trials more quickly and with reduced cost. And now, this includes understanding how to design clinical trials that yield the types of data that payers need to make appropriate reimbursement and formulary decisions."
"It's about making a difference in the lives of patients," said Gallup. "This move will help us make our vision of a more innovative, accessible healthcare marketplace a reality."
The merger is expected to close in the second half of 2022 subject to customary closing conditions and regulatory approvals.
At Norstella, our mission is simple: to help patients gain access to life–saving therapies. Norstella consists of several prominent organizations""Evaluate, MMIT, Panalgo and The Dedham Group""that have united to offer a full range of pharmaceutical consultancy services and solutions. As one organization, Norstella provides life sciences clients with the right tools and expertise to navigate complexities at each step of the drug development life cycle, from pipeline to patient. For more information, visit Norstella and follow on LinkedIn.
Citeline (formerly Pharma Intelligence) powers a full suite of complementary business intelligence offerings to meet the evolving needs of health science professionals to accelerate the connection of treatments to patients and patients to treatments. These patient–focused solutions and services deliver and analyze data used to drive clinical, commercial, and regulatory related–decisions and create real–world opportunities for growth.
Our global teams of analysts, journalists and consultants keep their fingers on the pulse of the pharmaceutical, biomedical and medtech industries, covering it all with expert insights: key diseases, clinical trials, drug R&D and approvals, market forecasts and more. For more information on one of the world's most trusted health science partners, visit Citeline.